Business Updates

To, Date: August 13th, 2026 The Manager – Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: 1. M/s. Lord’s Mark Industries Limited; Scrip code – 501261 Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Business and Strategic Updates Dear Sir / Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you of the following developments in the business of Lord’s Mark Industries Limited. These developments span the Company’s diagnostics, medical devices, healthcare delivery and renewable energy businesses, and together mark a significant broadening of the Company’s healthcare platform alongside a proposed restructuring of its energy business. 1. Financial guidance for FY2027. The Company expects consolidated revenue of at least ₹1,550 crore in FY2027, representing growth of over 20% compared to FY2026, and PAT of at least ₹178 crore, at a margin of 11.4%, representing growth of over 50% and a margin inflection of at least 200bps compared to FY2026. The majority of the growth in FY2027 is expected to be driven by the Company’s base businesses of in vitro diagnostics and renewable energy & LED. The Company further expects a material step-up in contribution from FY2028 onward from the sickle cell testing business, alongside the medical devices business – comprising Onco Spectra and TB Truth – which commences meaningful commercialisation in FY2028. 2. Proposed demerger of the Renewable Energy & LED division into Lords Shakti Power Limited. The Board proposes to demerge the Company’s renewable energy and LED business into a separate entity, Lords Shakti Power Limited, in which the Company will hold 60%, with existing shareholders of the Company receiving shares in the resulting entity in proportion to their holdings. The scheme is proposed to be filed by March 2027. The demerger will allow the energy business to pursue its capital programme while enabling the remaining healthcare and diagnostics businesses to be valued on their own fundamentals. Lords Shakti Power Limited will enter into the power transmission business via the manufacturing of transformers. 3. Exclusive agreement with a leading global manufacturer for CAR-T cell therapy in India. The Company is set to enter into an exclusive India agreement with a leading global CAR-T manufacturer. Under the agreement, the Company will establish laboratory and treatment capability across five centres in India, with the first two planned at Mumbai and Bangalore and targeted to commence by March 2027. CAR-T therapy is presently accessible to only a very small number of patients in India owing to its cost; the Company intends to offer treatment at a substantially lower price point than currently available, materially expanding the addressable patient population. 4. Incorporation of Lords Mark Industries UK Limited. The Company has established a subsidiary in the United Kingdom, being the first Indian company to register in the United Kingdom following the India–UK Free Trade Agreement, targeted to be operational from January 2027. The entity will operate its own pathology laboratory — supplied entirely with rapid test kits, analysers and biochemistry reagents manufactured and exported by the Company — and will additionally supply diagnostic materials to other laboratories in the United Kingdom. An application for NHS approval has been submitted. The subsidiary opens a developed-market channel for the Company’s IVD manufacturing base at international price points. 5. Incorporation of Lords Mark Industries Swiss Limited. The Company is under process to establish a subsidiary in Switzerland pursuing the same business plan as the United Kingdom entity — a captive pathology laboratory supplied from the Company’s Indian manufacturing base, alongside wholesale supply to laboratories in that market — extending the Company’s regulated-market presence into continental Europe. 6. Incorporation of Lords Mark Medicine Limited and oncology hospital programme. The Company has established a subsidiary, Lords Mark Medicine Limited, to enter healthcare delivery through a network of owned oncology hospitals in tier-2 cities, addressing a market where approximately 70% of districts lack a comprehensive cancer care centre and radiotherapy capacity stands at 0.6 machines per million population against a WHO norm of 1–3. The programme commences with two pilot hospitals of approximately 70 beds each at Vapi and Solapur, targeted to open by March 2027 and proposed to be funded through a debt raise of approximately ₹200 crore in December 2026. A feasibility and city-selection study by a leading global consulting firm is underway. The hospital network is also expected to provide a captive channel for the Company’s diagnostics and medical device businesses. 7. Dialysis centre network — 50 centres by March 2027. The Company proposes to establish 50 dialysis centres across India by March 2027, operated by the Company from rented premises and equipped with 3 to 5 of its own RENALOS dialysis machines per centre. The rented-premises model keeps the capital requirement per centre limited to equipment and fit-out, enabling rapid expansion, while in-house manufacture of the machines allows the network to be equipped at cost. The centre network shifts the Company’s dialysis business from equipment sales alone toward recurring, session-based service revenue. 8. OneDNA genomic testing platform — patient trials completed; ICMR approval received. The Company has completed patient trials for its OneDNA genomic testing platform and has received approval from the Indian Council of Medical Research, with an application to the Central Drugs Standard Control Organisation (CDSCO) under process. extends the Company’s diagnostics portfolio into genomics-led preventive and personalised healthcare. 9. Biomescan Analytics Platform — manufacturing licence received. As previously intimated on 10 August 2026, the Company became the first and only company in India to receive a manufacturing licence for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD) under the Medical Devices Rules, 2017, for its Biomescan Analytics Platform, licensed as a wellness and health-information tool for preventive healthcare and early health risk assessment. Statement from Management: Commenting on the developments, Mr. Sachidanand Upadhyay, Managing Director, Lord’s Mark Industries Ltd., stated: "Lord's Mark today stands at the most important inflection point in its history. Over the past decade we have built profitable, scaled businesses in diagnostics and renewable energy, the foundations of which now fund our next chapter. The guidance we have issued reflects the strength of our existing operations, with top-line growth of at least 20% and PAT growth of at least 50%. The subsequent announcements are what we build on top of them: cancer care reaching India’s rural districts, advanced CAR-T therapy at affordable prices for Indian patients, and Indian- made diagnostics serving laboratories from the UK to Switzerland. Healthcare in India is moving from scarcity to access, and Lord's Mark intends to be one of the companies that makes that happen." Thanking You, For Lord’s Mark Industries Limited (Formerly known as Lords Mark India Limited and Kratos Energy & Infrastructure Limited) Mr. Sachidanand Hariram Upadhyay Managing Director (DIN No: - 01631728)